Definitive Contract 75D30121C10501
Award Date
3/12/21
Potential Completion Date
3/11/22
Potential Value
$16M
Federal Agency
CDC Pittsburgh
Awardee
The Broad Institute, Inc.
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02142, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Broad Institute, Inc. was awarded a $4.4 million definitive cost-no-fee contract by the Centers for Disease Control and Prevention to support applied research addressing the continued public health emergency posed by COVID-19. Under the contract, the Broad Institute will sequence SARS-CoV-2 virus samples and conduct epidemiological analysis in collaboration with two major subcontractors, the Massachusetts General Hospital and the University of Massachusetts Medical School. The subcontractors...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $2.5 million definitive contract to the Scripps Research Institute for genomic sequencing of SARS-CoV-2 to investigate local and cross-border emergence and spread. This contract was awarded under the Centers for Disease Control COVID-19 Broad Agency Announcement, which sought white papers related to developing strategies for protecting communities from COVID-19, including examining the virus's...
The Centers for Disease Control and Prevention awarded a $4,600,633 definitive cost-no-fee contract to The Broad Institute, Inc. to demonstrate pan-pathogen and pathogen-agnostic genomic surveillance of clinical respiratory disease. As a non-profit research organization, The Broad Institute will leverage its expertise in large-scale genomic and health data analysis, integration and management to support the CDC's infectious disease initiatives. No set-aside designation was used for this award...
The Centers for Disease Control and Prevention (CDC) awarded a $39.9 million firm fixed price definitive contract to Aegis Sciences Corporation for COVID-19 genome sequencing services. As the prime contractor, Aegis Sciences Corporation will perform the sequencing work out of its Nashville, Tennessee laboratory. The one year contract is intended to support the CDC's ongoing efforts to track genetic variations of the SARS-CoV-2 virus through genomic surveillance. No subcontractors or set aside...
This is a $2,226,582.00 firm fixed-price definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard. The contract is for FY22 BAA TOPIC 7 and has a completion date of March 25, 2025. The Broad Institute is a non-profit biomedical and genomic research organization that frequently partners with government agencies like the NIH, CDC, DoD, and NSF to provide specialized scientific services...
The Centers for Disease Control and Prevention awarded a $600,000 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract calls for SARS-COV-2 SPHERES baseline genomic sequencing in support of the CDC's coronavirus COVID-19 programs. Performance will take place in San Diego through March 2021. As the leading public health agency in the U.S., the CDC routinely sequences virus genomes to track disease spread and evolution, providing genomic surveillance critical...
The Centers for Disease Control and Prevention awarded a $3.975 million firm fixed price definitive contract to Illumina, Inc. of San Diego, California. The contract is for SARS-COV-2 SPHERES Baseline Genomic Sequencing to support the Department of Health and Human Services and CDC's efforts responding to the Coronavirus Disease 2019 (COVID-19) pandemic. Under this contract, Illumina will provide genomic sequencing and data analysis services to establish a baseline of SARS-CoV-2 virus genomes...
This contract is for research and development services awarded by the Centers for Disease Control and Prevention (CDC) to The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard. The contract has a ceiling value of $1,029,999.88 and a completion date of September 29, 2026. It is a definitive contract with a cost-no-fee pricing type, and there is no set-aside designation. The Broad Institute is a non-profit biomedical and genomic research organization that frequently...
The Centers for Disease Control and Prevention (CDC) awarded a firm-fixed-price purchase order to Illumina, Inc. for $128,657.11 to provide whole genome sequencing kits. The award has an ultimate completion date of September 30, 2024. This award was made under an unrestricted solicitation, RFQ 75D301-24-Q-77983, which sought commercial items related to whole genome sequencing for antimicrobial resistance surveillance, including NovaSeq 6000 SP Reagent Kits, NovaSeq XP 2-Lane Kits, ILMN DNA LP...
This is a firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the provision of Genomic Sequencing Kits with a ceiling value of $170,641.14 and a performance period ending on August 28, 2024. The contract does not utilize a set-aside designation. Illumina is the prime contractor and has been awarded multiple federal contracts...